VERV News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders

VERV

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

VERV

BALA CYNWYD, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders

VERV

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Halper Sadeh encourag

Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

VERV

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Verve will receive $10.50 per share in cash (an aggregate of approximately $1.

Verve Therapeutics Q1 EPS $(0.35) Versus $(0.59) YoY, Sales $32.98M

VERV

May 14, 2025
Read more →

Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight

VERV

April 15, 2025
Read more →

Guggenheim Maintains Buy on Verve Therapeutics, Raises Price Target to $24

VERV

April 15, 2025
Read more →

Canaccord Genuity Maintains Buy on Verve Therapeutics, Raises Price Target to $39

VERV

April 15, 2025
Read more →

Assessing Verve Therapeutics: Insights From 4 Financial Analysts

VERV

April 14, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Verve Therapeutics, Raises Price Target to $25

VERV

April 14, 2025
Read more →

Verve Therapeutics Reports Results for Heart-2 Trial, Achieving 69% LDL-C Reduction with VERVE-102

VERV

April 14, 2025
Read more →

Verve Therapeutics Receives FDA Fast Track Designation For Its VERVE-102 In Vivo Base Editing Medicine Targeting PCSK9

VERV

April 11, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target

VERV

March 25, 2025
Read more →

Verve Therapeutics Reports Clearance Of IND Application By FDA For VERVE-102 For Treatment Of Patients Living With Heterozygous Familial Hypercholesterolemia And/Or Premature Coronary Artery Disease

VERV

March 24, 2025
Read more →

RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $15

VERV

March 4, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Verve Therapeutics, Raises Price Target to $15

VERV

February 28, 2025
Read more →

Verve Therapeutics Advances Heart-2 Trial, Expects Key 2025 Milestones In Cardiovascular Gene Therapy

VERV

February 27, 2025
Read more →

Verve Therapeutics Says Well-capitalized With Cash Runway Extending Into Mid-2027

VERV

January 13, 2025
Read more →

RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $17

VERV

November 6, 2024
Read more →

Analyst Scoreboard: 4 Ratings For Verve Therapeutics

VERV

November 6, 2024
Read more →

HC Wainwright & Co. Maintains Buy on Verve Therapeutics, Lowers Price Target to $14

VERV

November 6, 2024
Read more →

Verve Therapeutics Ended Q3 2024 With Cash, Cash Equivalents, And Marketable Securities Of $539.9M With Cash Runway Through 2026

VERV

November 5, 2024
Read more →

Verve Therapeutics Q3 2024 GAAP EPS $(0.59) Beats $(0.69) Estimate, Sales $6.87M Beat $2.81M Estimate

VERV

November 5, 2024
Read more →